Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
ZVRA Quote, Financials, Valuation and Earnings
Last price:
$8.66
Seasonality move
:
-1.31%
Day range:
$8.42 - $8.72
52-week range:
$6.19 - $13.16
Dividend yield:
0%
P/E ratio:
13.70x
P/S ratio:
5.59x
P/B ratio:
3.65x
Volume:
635.5K
Avg. volume:
1.1M
1-year change:
0.58%
Market cap:
$486.4M
Revenue:
$23.6M
EPS (TTM):
$0.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZVRA
Zevra Therapeutics, Inc.
|
$26.6M | -$0.02 | 132.94% | -99.63% | $22.54 |
|
AKBA
Akebia Therapeutics, Inc.
|
$56.4M | -$0.01 | 20.82% | -95.21% | $5.40 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NKTR
Nektar Therapeutics
|
$10.2M | -$2.79 | -64.24% | -1474.64% | $114.43 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
XOMA
XOMA Royalty Corp.
|
$11.5M | $0.04 | 27.73% | -80.01% | $64.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZVRA
Zevra Therapeutics, Inc.
|
$8.64 | $22.54 | $486.4M | 13.70x | $0.00 | 0% | 5.59x |
|
AKBA
Akebia Therapeutics, Inc.
|
$1.70 | $5.40 | $449.8M | -- | $0.00 | 0% | 1.89x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NKTR
Nektar Therapeutics
|
$43.94 | $114.43 | $760.2M | -- | $0.00 | 0% | 45.31x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
XOMA
XOMA Royalty Corp.
|
$25.99 | $64.50 | $321.8M | 34.86x | $0.54 | 0% | 9.04x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZVRA
Zevra Therapeutics, Inc.
|
32.02% | 1.762 | 11.73% | 8.25x |
|
AKBA
Akebia Therapeutics, Inc.
|
83.68% | 1.611 | 29.46% | 1.76x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.157 | 16.97% | 4.07x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
XOMA
XOMA Royalty Corp.
|
54.99% | 1.936 | 26.95% | 3.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZVRA
Zevra Therapeutics, Inc.
|
$24.5M | $4.1M | 24.95% | 44.06% | 15.9% | $4.2M |
|
AKBA
Akebia Therapeutics, Inc.
|
$49.1M | $4.4M | -7.86% | -- | 7.57% | $28M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
XOMA
XOMA Royalty Corp.
|
$8.5M | -$1.3M | 7.44% | 17.31% | -14.22% | -$957K |
Zevra Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ZVRA or AKBA?
Akebia Therapeutics, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of 0.92%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Akebia Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZVRAZevra Therapeutics, Inc.94.04% -$0.01 $195.9M AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M -
What do Analysts Say About ZVRA or AKBA?
Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 160.92%. On the other hand Akebia Therapeutics, Inc. has an analysts' consensus of $5.40 which suggests that it could grow by 227.27%. Given that Akebia Therapeutics, Inc. has higher upside potential than Zevra Therapeutics, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Zevra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZVRAZevra Therapeutics, Inc.6 0 0 AKBAAkebia Therapeutics, Inc.4 0 0 -
Is ZVRA or AKBA More Risky?
Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison Akebia Therapeutics, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.934%.
-
Which is a Better Dividend Stock ZVRA or AKBA?
Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akebia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Akebia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVRA or AKBA?
Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are smaller than Akebia Therapeutics, Inc. quarterly revenues of $58.8M. Zevra Therapeutics, Inc.'s net income of -$544K is lower than Akebia Therapeutics, Inc.'s net income of $540K. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.70x while Akebia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus 1.89x for Akebia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVRAZevra Therapeutics, Inc.5.59x 13.70x $26.1M -$544K AKBAAkebia Therapeutics, Inc.1.89x -- $58.8M $540K
-
Which has Higher Returns ZVRA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of -255.85%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ZVRAZevra Therapeutics, Inc.94.04% -$0.01 $195.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ZVRA or NBY?
Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 160.92%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Zevra Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Zevra Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZVRAZevra Therapeutics, Inc.6 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ZVRA or NBY More Risky?
Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ZVRA or NBY?
Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVRA or NBY?
Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Zevra Therapeutics, Inc.'s net income of -$544K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.70x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVRAZevra Therapeutics, Inc.5.59x 13.70x $26.1M -$544K NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns ZVRA or NKTR?
Nektar Therapeutics has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of -301.29%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital ZVRAZevra Therapeutics, Inc.94.04% -$0.01 $195.9M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About ZVRA or NKTR?
Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 160.92%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 160.42%. Given that Zevra Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Zevra Therapeutics, Inc. is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ZVRAZevra Therapeutics, Inc.6 0 0 NKTRNektar Therapeutics6 1 0 -
Is ZVRA or NKTR More Risky?
Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.
-
Which is a Better Dividend Stock ZVRA or NKTR?
Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVRA or NKTR?
Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Zevra Therapeutics, Inc.'s net income of -$544K is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.70x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus 45.31x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVRAZevra Therapeutics, Inc.5.59x 13.70x $26.1M -$544K NKTRNektar Therapeutics45.31x -- $11.8M -$35.5M
-
Which has Higher Returns ZVRA or PTN?
Palatin Technologies has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of --. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZVRAZevra Therapeutics, Inc.94.04% -$0.01 $195.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ZVRA or PTN?
Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 160.92%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Zevra Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Zevra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZVRAZevra Therapeutics, Inc.6 0 0 PTNPalatin Technologies0 0 0 -
Is ZVRA or PTN More Risky?
Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ZVRA or PTN?
Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVRA or PTN?
Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than Palatin Technologies quarterly revenues of --. Zevra Therapeutics, Inc.'s net income of -$544K is higher than Palatin Technologies's net income of --. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.70x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVRAZevra Therapeutics, Inc.5.59x 13.70x $26.1M -$544K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ZVRA or XOMA?
XOMA Royalty Corp. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of 52.48%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat XOMA Royalty Corp.'s return on equity of 17.31%.
Company Gross Margin Earnings Per Share Invested Capital ZVRAZevra Therapeutics, Inc.94.04% -$0.01 $195.9M XOMAXOMA Royalty Corp.90.59% $0.70 $239.9M -
What do Analysts Say About ZVRA or XOMA?
Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 160.92%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 148.17%. Given that Zevra Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Zevra Therapeutics, Inc. is more attractive than XOMA Royalty Corp..
Company Buy Ratings Hold Ratings Sell Ratings ZVRAZevra Therapeutics, Inc.6 0 0 XOMAXOMA Royalty Corp.4 0 0 -
Is ZVRA or XOMA More Risky?
Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.
-
Which is a Better Dividend Stock ZVRA or XOMA?
Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZVRA or XOMA?
Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Zevra Therapeutics, Inc.'s net income of -$544K is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.70x while XOMA Royalty Corp.'s PE ratio is 34.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus 9.04x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVRAZevra Therapeutics, Inc.5.59x 13.70x $26.1M -$544K XOMAXOMA Royalty Corp.9.04x 34.86x $9.4M $10.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
